

**ASCO 2025
Plenary
session**

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Jean Bourhis et al.

Plenary session



FIRST / GINECO & ENGOT-ov44

A phase 3 clinical trial of dostarlimab (dost) and niraparib(nira) in first-line (1L) advanced ovarian cancer (aOC).

Anne-Claire Hardy-Bessard et al.

Oral session



TRUST / ENGOT ov-33

Trial of radical upfront surgical therapy in advanced ovarian cancer.

Sven Mahner et al.

Oral session

KEYNOTE A18 / ENGOT-cx11

Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer : final analysis results of the phase 3, randomized, double-blind.

Linda R. Duska et al.

Oral session

ROSELLA / ENGOT-ov72 Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer.

Alexander Olawaiye et al.

Oral session



GINECO SALVOVAR / ENGOT-ov78

A pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

Benoit You et al.

Poster

ENGAGe-IMPROVE / EXPRESSION XI

Quality of life and lifestyle changes during and after therapy in women with endometrial cancer: A global study of 1,660 patients.

Jalid Sehouli et al.

Poster



PRIMA / ENGOT-ov26

Impact of disease progression on health-related quality of life (HRQOL): Updated results. Trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Mark S. Shahin et al.

Poster

TROFUSE 020 / ENGOT-cx20A phase 3 randomized active-controlled, open label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-list treatment for recurrent or metastatic cervical cancer.

Ritu Salani et al.

Poster



GINECO PAOLA HRD - Translational Research

Genomic instability score (GIS) and benefit from olaparib (ola) and bevacizumab (bev) maintenance in high-grade ovarian cancer (HGOC): phase III PAOLA-1/ENGOT-ov25 trial exploratory analysis.

Jose Sandoval et al.

Poster session

GINECO PAOLA HRD - Translational Research

Assessment of homologous recombination deficiency and BRCA status in ovarian cancer: Analytical performance and relevance of a decentralized NGS assay for comprehensive genomic profiling.

Mohit Gupta et al.

Poster session

FFCD

5-FU + Naliri, Gemcitabine plus Nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma a randomized phase II comparative study (FUNGEMAX-PRODIGE 61).

Julien Taieb

Poster session



GERCOR

Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.

Antony Turpin

Oral session



IFM

Efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study.

Aurore Perrot

Oral session



IFCT



An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.

David Spigel

Poster session - ASCO Press Program

Molecular profiling and survival in oncogene-addicted resected stage IIIAN2 non-small cell lung cancer (NSCLC): A study from the Lung ART IFCT 0503 trial.

Victor Albarran-Artahona

Poster session

Pathomics-based prediction of thymic epithelial tumor subtypes within the French RYTHMIC network.

Lodovica Zullo

Poster session